Profile of exhaled‐breath volatile organic compounds to diagnose pancreatic cancer. BJS 2018; 105: 1493-1500.
Published: 18th July 2018
Authors: S. R. Markar, B. Brodie, S.‐T. Chin, A. Romano, D. Spalding, G. B. Hanna et al.
Pancreatic cancer has a very poor prognosis as most patients are diagnosed at an advanced stage when curative treatments are not possible. Breath volatile organic compounds (VOCs) have shown potential as novel biomarkers to detect cancer. The aim of the study was to quantify differences in exhaled breath VOCs of patients with pancreatic cancers compared with cohorts without cancer.
Patients were recruited to an initial development cohort and a second validation cohort. The cancer group included patients with localized and metastatic cancers, whereas the control group included patients with benign pancreatic disease or normal pancreas. The reference test for comparison was radiological imaging using abdominal CT, ultrasound imaging or endoscopic ultrasonography, confirmed by histopathological examination as appropriate. Breath was collected from the development cohort with steel bags, and from the validation cohort using the ReCIVA™ system. Analysis was performed using gas chromatography–mass spectrometry.
A total of 68 patients were recruited to the development cohort (25 with cancer, 43 no cancer) and 64 to the validation cohort (32 with cancer, 32 no cancer). Of 66 VOCs identified, 12 were significantly different between groups in the development cohort on univariable analysis. Receiver operating characteristic (ROC) curve analysis using significant volatile compounds and the validation cohort produced an area under the curve of 0·736 (sensitivity 81 per cent, specificity 58 per cent) for differentiating cancer from no cancer, and 0·744 (sensitivity 70 per cent, specificity 74 per cent) for differentiating adenocarcinoma from no cancer.
Breath VOCs may distinguish patients with pancreatic cancer from those without cancer.Full text
You may also be interested in
Randomized clinical trial
Randomized trial of two types of gastrojejunostomy after pancreatoduodenectomy and risk of delayed gastric emptying (PAUDA trial).
Authors: J. Busquets, S. Martín, J. Fabregat, L. Secanella, N. Pelaez, E. Ramos et al.
Notes: No difference in outcomes
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Cost‐effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.
Authors: G. M. W. Bjørnelv, S. Dueland, P.‐D. Line, P. Joranger, Å. A. Fretland, B. Edwin et al.
Notes: Not for every country
Mitochondrial function after associating liver partition and portal vein ligation for staged hepatectomy in an experimental model.
Authors: A. Budai, G. Horváth, L. Tretter, Z. Radák, E. Koltai, Z. Bori et al.
Notes: Defines the biochemical basis
Authors: M. Del Chiaro, K. Søreide
Multicentre study of the prognostic impact of preoperative bodyweight on long‐term prognosis of hepatocellular carcinoma.
Authors: J. J. Yu, F. Shen, T. H. Chen, L. Liang, J. Han, H. Xing et al.
Notes: BMI matters
Importance of main pancreatic duct dilatation in IPMN undergoing surveillance. BJS 2018; 105: 1825-1834.
Authors: G. Marchegiani, S. Andrianello, G. Morbin, E. Secchettin, M. D'Onofrio, R. De Robertis et al.
Notes: Duct dilatation no risk alone
Pancreas‐sparing, ampulla‐preserving duodenectomy for major duodenal (D1–D2) perforations. BJS 2018; 105: 1487-1492.
Authors: S. Di Saverio, E. Segalini, A. Birindelli, S. Todero, M. Podda, A. Rizzuto et al.
Notes: Useful option
Outcomes of pancreas retransplantation in patients with pancreas graft failure. BJS 2018; 105: 1816-1824.
Authors: S. Gasteiger, B. Cardini, G. Göbel, R. Oberhuber, F. Messner, T. Resch et al.
Notes: Good outcome in selected patients
Meta‐analysis of the prognostic role of perioperative platelet count in posthepatectomy liver failure and mortality. BJS 2018; 105: 1254-1261.
Authors: A. Mehrabi, M. Golriz, E. Khajeh, O. Ghamarnejad, P. Probst, H. Fonouni et al.
Notes: Low platelets, worse outcomes
Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. BJS 2018; 105: 1408-1416.
Authors: N. T. E. Bird, A. McKenna, J. Dodd, G. Poston, R. Jones, H. Malik et al.
Notes: Tumour biology is important
Authors: Y. Kishi, S. Nara, M. Esaki, N. Hiraoka, K. Shimada
Notes: Standardized lymphadenectomy is important